See the impact of dupixent since its initial approval
prescribed by pulmonologists3,b
patients on therapy across
approved indications
worldwide4,c
aAs designated by the US Food and Drug Administration (FDA).2
b#1 prescribed biologic by pulmonologists includes
the aggregate number of new to brand across all indications. Source: Data on file, Sanofi US. New to
Brand
Monthly Audit; data through June 2024.3
cThis worldwide number is largely comprised from
10 countries (Canada, China, France, Germany, Italy, Japan, the Netherlands, Spain, the UK, and the
US),
with the rest of the world comprising ≈10% of this number. This number is comprised of the following US
approved indications: AD, asthma,
CRSwNP, PN, and EoE. Data through August
2024.4
A BREAKTHROUGH THERAPY
IN COPD1,2,a
DUPIXENT has the ability to:
Reduce
Exacerbations
Up to
Moderate or severe exacerbation rate reduction at Week
52 (annualized rate)
(NOTUS primary
endpoint)1,d,e
Improve
Patients’ breathing and quality of
life
Improvement in
post-bronchodilator
FEV1
BOREAS:
- 158 mL improvement for DUPIXENT + SOC (n=468) vs 84 mL for placebo + SOC (n=471) at Week 12
NOTUS:
- 134 mL improvement for DUPIXENT + SOC (n=470) vs 67 mL for placebo + SOC (n=465) at Week 12
Post-bronchodilator lung function results are descriptive. Definitive conclusions cannot be made.
Improvement in quality of life as measured by SGRQ1,5
51% of patients in the BOREAS trial reported a clinically meaningful (≥4-point) improvement at Week 52 with DUPIXENT vs 43% for placebo (N=939; OR: 1.44; 95% CI: 1.10, 1.89; P=0.009).
- In the NOTUS trial, there was a 51% responder rate at Week 52 for subjects treated with DUPIXENT vs 47% for placebo (N=721; OR: 1.16; 95% CI: 0.86,1.58)1,6
NOTUS results are descriptive. Definitive conclusions cannot be made.
Target
TWO OF THE KEY DRIVERS OF TYPE 2
INFLAMMATION
IL-4 and IL-13 are two of the key drivers of local and systemic inflammation1
The mechanism of dupilumab action has not been definitively established.1
- The most common adverse reactions (incidence ≥2%) are viral infection, headache, nasopharyngitis, back pain,
diarrhea, arthralgia, urinary tract
infection, local administration reaction, rhinitis, eosinophilia, toothache, and gastritis1
dModerate exacerbations were exacerbations that
resulted in treatment with a systemic glucocorticoid, an antibiotic agent, or both. Severe
exacerbations were
exacerbations that led to hospitalization or an emergency department visit or that resulted in
death.1
eAt Week 52 in the NOTUS trial, patients treated with
DUPIXENT + SOC (n=470) experienced an annualized rate of 0.86 moderate or severe exacerbations
vs 1.30 for those
treated with placebo + SOC (n=465). Rate ratio vs placebo was 0.66 (95% CI: 0.54, 0.82) (P<0.001; primary
endpoint). At Week 52 in the
BOREAS trial, patients administered DUPIXENT + SOC (n=468) experienced 30%
reduction (0.78 vs 1.10) in moderate or severe exacerbations vs placebo
+ SOC (n=471) (rate ratio: 0.70 [95% CI:
0.58, 0.86]; P<0.001).1,5,6
Mechanism of Action (MOA)
DUPIXENT is the first and only biologic to
target two of the key drivers of type 2
inflammation in COPD.1
Demonstrated Efficacy
Learn about the results of DUPIXENT on
exacerbations, lung function, and quality of life
for COPD patients.1,5,6
The mechanism of dupilumab action has not been definitively established.
COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in 1 second; OR, odds ratio; SGRQ, St George’s Respiratory Questionnaire; SOC, standard of care.
DUPIXENT MyWay is a patient support program that can help enable access to DUPIXENT and
offers financial assistance for eligible patients, one-on-one nursing support, and more.
Contact a Field Representative
Connect with a DUPIXENT Field Representative to get answers to your product-related questions.